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Figure 1. Transcriptional Differences between 2i and Serum-Grown mESCs
Schematic diagram of mESC growth conditions (top), transcriptome (middle), and RNA Polymerase II
pausing differences (bottom, Pol II) in mESCs grown in 2i (left) or serum (right). Reads indicate ChIP-
Seq reads. Models for lineage-specification genes are shown below the graphs in black, and start sites
are indicated by an arrow. The transcriptional state of mESCs grown in either condition is readily intercon-
verted by changing the growth media.
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Previewsand maintaining the ground state of naive
pluripotent ESCs.
Marks et al. (2012) found that the
transcriptional and chromatin states of
mESCs were interconvertable when cells
were switched from one growth condition
to the other. This observation indicates
that whatever molecular memory mESCs
have of one state is rapidly lost when
exposed to the other condition.
Cultured human ESCs have features
that indicate that they are more develop-
mentally advanced thanmESCs,and thereis considerable interest in isolating human
pluripotent stemcells in amore naive state
(reviewed in De Los Angeles et al., 2012).
This is challenging because the simple
applicationof2i conditions tocells isolated
from preimplantation human embryos or
from reprogramming has thus far failed to
produce naive human ESCs/iPSCs. It
seems likely that naive human ESCs will
eventually be isolated, and it will then be
interesting to determine if enhanced Pol II
pausing and other features of the tran-
scriptional and chromatin landscapeCell Stem Cedescribed by Marks et al. (2012) are also
found in these human cells.REFERENCES
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Achieving immune tolerance through cell transplantation is a promising approach for treating autoimmune
disease. In this issue of Cell Stem Cell, Akiyama et al. (2012) demonstrate that human and mouse mesen-
chymal stem cells can induce immune suppression by attracting and killing autoreactive T cells, which
stimulates TGFb production by macrophages and generates regulatory T cells.Mesenchymal stem cells/marrow stromal
cells (MSCs) are perhaps the cell type
most commonly investigated for tissuerepair therapies. However, MSCs appear
capable of doing much more than simply
facilitating tissue repair. These interestingcells, derived most often from the bone
marrow or fat, can serve as ‘‘paramedics’’
to help heal tissue through local andll 10, May 4, 2012 ª2012 Elsevier Inc. 485
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Previewssystemic secretion of a diverse array of
cytokines. To date, MSCs from bone
marrow and adipose tissue have been
extensively tested and proven effective
in preclinical animal models of many
injuries and disorders and are actively
being investigated clinically for many
disease states (reviewed in Meyerrose
et al., 2010). Following systemic delivery,
MSCs are capable of extensive migration,
in particular to areas of hypoxia, inflam-
mation, or other tissue injury, and release
trophic factors that hasten endogenous
repair (Caplan and Correa, 2011).
These secreted bioactive products can
enhance angiogenesis, inhibit fibrosis
and apoptosis, and stimulate recruitment,
retention, proliferation, and differentiation
of tissue-residing stem cells. Importantly,
MSCs appear to be potently immunosup-
pressive, as they can be infused without
tissue matching and are able to shield
themselves from the host immune attack
(Tolar et al., 2010; English and Mahon,
2011). The ability to be transplanted
without tissue matching has allowed large
multicenter trials to be conducted with
direct comparison of the same batches
of MSCs without adverse events or overt
rejection reactions. Human MSCs are
currently being tested in clinical trials for
numerous applications including, but not
limited to, myocardial infarction, stroke,
knee injury, Crohn’s disease, critical limb
ischemia, neurodegenerative disorders,
kidney disease, graft-versus-host disease
(GVHD), and various autoimmune disor-
ders (Caplan and Correa, 2011; Tolar
et al., 2010). It is their immunosuppressive
capability that attracts much attention
because it not only allows for a greater
donor pool to choose from but also may
allow their use in transplantation and
promoting donor engraftment. However,
the mechanisms by which MSCs modu-
late immune function have been difficult
to decipher. Nonetheless, these cells
would seem uniquely suited to be used
clinically in autoimmune states due to
their immunomodulatory capabilities as
well as their regenerative abilities.
In the current issue of Cell Stem Cell,
Akiyama et al. (2012) report a fascinating
new mechanism by which MSCs exert
their immunosuppressive effects through
multiple paracrine interactions and cell-
cell contacts. MSCs appear to express
functional FAS ligand (FASL), more com-
monly associated as a potent effector486 Cell Stem Cell 10, May 4, 2012 ª2012 Elarm of cytotoxic T cells, and after adop-
tive transfer were shown to be capable
of directly mediating apoptosis of host
T cells that express FAS. This effect was
specific for the FAS-FASL interaction
because FASL-deficient MSCs failed to
promote T cell apoptosis. Another novel
(and complex) twist in this scenario is
that MSCs first lure autoreactive T cells
via the chemokine MCP-1, and this
chemokine is induced by triggering of
FAS on the MSC, creating a complex
dance in which both ends of FAS-FASL
interactions act on the MSC. This path-
way of inducing T cell attraction repre-
sents a novel means to increase the likeli-
hood that the host T cells will come into
contact with the MSC. Death of the
effector T cells via FASL is only part of
the story because their demise also
causes the production of TGFb by macro-
phages, which engulf the dying cells, and
then leads to generation of potently
immunosuppressive regulatory T cells
(Tregs), which further suppress immune
function. Thus, MSCs are capable of
potent immunosuppression via a multi-
pronged approach consisting of both
direct and indirect effects.
What makes the study by Akiyama so
informative is that, although there have
been significant differences between
mouse and human MSCs with regard to
the pathways used in immune suppres-
sion (Ren et al., 2009), the study shows
similar effects and end results of MSCs
in both a mouse model of colitis and
patients with systemic sclerosis. In both
cases, allogeneic MSC transfer resulted
in T cell loss, increase in Treg numbers,
and significant resolution of disease
pathology. This study raises tantalizing
possibilities with regards to application
of this approach for other autoimmune
disorders and organ transplantation.
MSCs appear to exert their immuno-
suppressive effects by acting as what
immunologists call ‘‘veto cells’’ in which
recognition by the host effector cells is
needed to trigger a reaction that leads to
their death. Here, reactive T cells come
into contact with a veto cell (in this case
an MSC) and are killed as a result. The
use of the veto phenomena has been
under examination using donor T and NK
cells as a means to promote deletion of
donor-reactive host T cells, thus resulting
in greater donor engraftment and perhaps
permanent immune tolerance in organsevier Inc.transplantation (Reich-Zeliger et al.,
2007). MSCs take it another step further
by providing the honey (MCP-1) to attract
the flies (host T cells). The study also
raises important questions with regards
to previous reports where the immuno-
suppressive capabilities of MSCs have
been less clear. If these cells have such
weapons in their arsenal, reports of allo-
geneic MSCs being immunogeneic and
rejected by recipient mice (Nauta et al.,
2006), and clinical trials using these cells
in GVHD (Tolar et al., 2010; Le Blanc
et al., 2008) yielding equivocal results
with regard to improvement of pathology,
show that much still needs to be delin-
eated with regards to clinical exploitation
of MSCs for immunosuppression. It will
also be important to ascertain the extent
of the immunosuppression that these
cells can exert using much more quan-
titative assays for in vivo immune re-
sponses. Other questions also are raised
as to how the triggering of FAS on the
MSC results in MCP-1 production and
not death. Clearly, there must be thresh-
olds in the spectrum of responses, and
these must be delineated to determine
and optimize their full potential.
The study also raises intriguing ques-
tions as to why such immunosuppressive
properties exist in these cells. It is
perhaps surprising that FASLis expressed
on a nonimmune cell type and even more
so that the cell has evolved to express
chemoattractants that draw T cells to
them. Maybe nature intended that these
cells have the ability to roam to sites of
organ damage to not only promote tissue
repair but to also immunosuppress at
their own discretion and prevent potential
autoimmune triggering that may occur at
the site of injury. Regardless of why, these
are properties that we are more than
happy to take advantage of in the clinic
for the treatment of various disease
states.REFERENCES
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While DNA cytosine methylation is relatively stable in somatic tissues, it is highly dynamic during preimplan-
tation development. A recent study in Nature by Meissner and colleagues (Smith et al., 2012) now reveals
dramatic shifts in DNA methylation during the earliest stages of mouse embryogenesis at genome scale
and base resolution.DNAmethylation at the 5-position of cyto-
sine (5mC) in mammals largely occurs at
CpG dinucleotides and is required for
normal embryogenesis. A global DNA
methylation landscape is first estab-
lished by de novo DNA methyltrans-
ferases Dnmt3a and Dnmt3b in the inner
cell mass (ICM) of blastocysts and is
stably inherited in somatic tissues through
the action of maintenance methylation
machineries. DNA methylation in somatic
cells generally displays a bimodal distri-
bution, in which the majority of CpG sites
are methylated and unmethylated CpGs
are primarily found in clusters termed
CpG islands (CGIs) that are frequently
associated with gene promoters (Deaton
and Bird, 2011). It is broadly accepted
that DNA methylation at gene promoters
and other regulatory sequences such as
enhancers inversely correlates with tran-
scription and may facilitate lineage re-
striction during development.
While the methylation pattern is stably
maintained in somatic tissues, mamma-
lian preimplantation development is
accompanied by a wave of genome-
wide demethylation and remethylation.Early studies using immunofluorescence
staining and locus-specific bisulphite
sequencing have indicated that DNA
methylation in the paternal genome is
rapidly removed via a replication-inde-
pendent process a few hours after fertil-
ization, while the maternal DNA methyla-
tion level is gradually reduced in a
replication-dependent manner with the
lowest level occurring at the blastocyst
stage (Mayer et al., 2000). Recent studies
have revealed that loss of 5mC in the
paternal genome in the zygote is primarily
initiated by Tet3 (Gu et al., 2011; Wossidlo
et al., 2011), a member of the Ten-eleven
translocation (Tet) family of DNA dioxyge-
nases capable of converting 5mC to 5-
hydroxymethylcytosine (5hmC), 5-formyl-
cytosine (5fC), and 5-carboxylcytosine
(5caC) through iterative oxidation (Wu
and Zhang, 2011). High-resolution meta-
phase chromosome immunostaining of
various stages of preimplantation em-
bryos using antibodies specific for 5mC,
5hmC, 5fC, and 5caC suggested that
the bulk 5mC in the paternal genome
is first oxidized to 5hmC/5fC/5caC in
zygotes, followed by replication-depen-dent dilution of 5hmC/5fC/5caC dur-
ing preimplantation development (Inoue
et al., 2011; Inoue and Zhang, 2011)
(Figure 1A). Although these studies have
revealed a global picture of how 5mC is
lost during preimplantation development,
it lacks the resolution for us to tell exactly
which part of the genome is subject to or
protected from this wave of DNA deme-
thylation. Bisulfite sequencing has been
the method of choice to generate single-
nucleotide resolution maps of DNA
methylation, and genome-wide bisulphite
sequencing of somatic and cancer
genomes continues to shed light on
genomic distribution and regulatory func-
tion of DNA methylation in tissue-specific
gene expression and tumorigenesis.
However, similar analysis for preimplan-
tation embryos has been difficult due to
limitations on the number of embryos
available.
In a recent issueofNature,Meissner and
colleagues have successfully overcome
this technical hurdle by using the reduced
representation bisulphite sequencing
(RRBS) technique and have generated
base-resolution and genome-scale mapsll 10, May 4, 2012 ª2012 Elsevier Inc. 487
